Pfizer's Doldrums, Just A Bad Case Of COVID-19?

CatEyePerspectiveIntroduction: A biotech stock with a large dividend is pretty uncommon since biotechnology and pharmaceutical companies tend to focus more on reinvestment into pipeline growth rather than shareholder returns. But as a biopharma grows larger and there may be a paucity of potential pipeline or partnership opportunities that may be worth investing in, the company may look to return some of its profits to its investors through either dividends or share repurchases. Pfizer (NYSE:PFE) seems t ...